Reata receives FDA approval for SKYCLARYS to treat Friedreich’s Ataxia
SKYCLARYS is an oral, once-daily medication, indicated for the treatment of Friedreich’s ataxia, an ultra-rare, inherited neurodegenerative disorder,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Mar 23
SKYCLARYS is an oral, once-daily medication, indicated for the treatment of Friedreich’s ataxia, an ultra-rare, inherited neurodegenerative disorder,…
27 Feb 23
China’s NMPA approval is based on results from the DESTINY-Breast03 clinical trial, in which Enhertu showed a 72%…
17 Feb 23
Lamzede is the first and only enzyme replacement therapy intended for the treatment of non-central nervous system manifestations…
14 Feb 23
The IND clearance by the FDA paves the way for the Dutch clinical-stage company to assess the safety…
13 Feb 23
FDA approved Jemperli for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after a prior…
08 Feb 23
Forxiga is already approved in more than 100 countries worldwide, to treat patients with type-2 diabetes (T2D), HFrEF…
06 Feb 23
Trodelvy is a Trop-2 directed antibody-drug conjugate, indicated for previously treated patients with metastatic hormone receptor (HR)-positive, human…
02 Feb 23
The US FDA approval of Jesduvroq is based on results from the ASCEND-D trial, which evaluated the efficacy…
30 Jan 23
Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a…
27 Jan 23
The EC approval is based on results from Phase 3 DESTINY-Breast04 clinical trial, in which Enhertu reduced the…